Daymark Health, a startup pushing to reshape the cancer care experience for patients, providers, and health plans, announced a $20mn Series A raise.
Healthier Capital and Blue Venture Fund co-led the round, with participation from Yosemite, Maverick Ventures, and Oncology Ventures, all of whom had backed the company earlier.
The model Daymark advances goes beyond clinical treatment. It combines physical and virtual services, offering patients navigation support, mental health care, 24/7 assistance, symptom management, and help with social needs.
A tech-enabled platform coordinates these services with oncologists and primary care physicians, while health plan partnerships align incentives to improve outcomes and curb total care costs.
CEO and co-founder Dr. Justin Bekelman, an oncologist, described a shift underway in oncology. Payers are increasingly burdened by specialty risk, and providers want solutions that feel patient-first.
He said Daymark was built to deliver compassionate, seamless cancer care at scale, and the company now has investor backing to extend its reach across the U.S.
We are seeing a tipping point in oncology, where payers feel the ongoing pressures of managing specialty risk and providers are seeking solutions that put patients first
Dr. Justin Bekelman, oncologist and CEO and Co-Founder of Daymark Health
“We built Daymark Health to provide compassionate, intelligent, and frictionless cancer care at scale and are honored to partner with our new investors to advance cancer care across the U.S.,” said Dr. Justin Bekelman.
Funding from Healthier Capital and Blue Venture Fund will fuel Daymark’s expansion, both in platform capabilities and in national partnerships with payers and providers.
The company aims to deliver its services to a much larger patient base in coming years. New board members include Dr. Aman Mahajan of Healthier Capital and Kelsey Maguire of Blue Venture Fund.
Healthier Capital, founded by former One Medical CEO Amir Dan Rubin, invests in technology-powered healthcare companies targeting better outcomes.
Blue Venture Fund, a $1.2bn collaboration among 36 Blue Cross Blue Shield organizations and Sandbox, has a long-standing focus on reshaping healthcare financing and delivery.
Their participation signals broad agreement that oncology requires new, more integrated models to keep pace with patient needs and rising costs.
Daymark’s backers argue the platform breaks down the fragmentation that has long defined cancer care. Mahajan called it a transformational, value-based model capable of lowering avoidable costs while personalizing care delivery.
Maguire emphasized alignment with Blue Venture Fund’s mission, describing the company’s role as ensuring patients feel seen, heard, and valued while improving outcomes.
Daymark is breaking down the silos in healthcare delivery to better enable personalized care for patients with cancer, while improving outcomes and reducing avoidable costs.
Aman Mahajan, MD, PhD, Partner at Healthier Capital
“Daymark is delivering a transformational model of personalized, high-quality, value-based cancer care.”
Daymark’s pitch rests on the belief that cancer care is moving toward a tipping point. For payers, specialty spend is a growing burden; for providers, siloed systems strain patients and staff alike.
The company sees its approach — a mix of virtual support, home-based services, and aligned incentives with health plans — as the path forward for value-based oncology in the U.S.
“Daymark and Blue Venture Fund are passionate about a shared purpose: to give all patients the best possible care experience, driving better health outcomes and ensuring they feel seen, heard, and valued,” said Kelsey Maguire, Managing Director at the Blue Venture Fund.
“We’re thrilled to partner with Daymark as they redefine the cancer care experience and evolve what’s possible in value-based oncology.”
